Open Access

LAMC2 is a potential prognostic biomarker for cholangiocarcinoma

  • Authors:
    • Khaa Hoo Ong
    • Yao-Yu Hsieh
    • Hong-Yue Lai
    • Ding-Ping Sun
    • Tzu-Ju Chen
    • Steven Kuan‑Hua Huang
    • Yu-Feng Tian
    • Chia-Lin Chou
    • Yow-Ling Shiue
    • Hung-Chang Wu
    • Ti-Chun Chan
    • Hsin-Hwa Tsai
    • Chien-Feng Li
    • Yu-Hsuan Kuo
  • View Affiliations

  • Published online on: October 30, 2023     https://doi.org/10.3892/ol.2023.14120
  • Article Number: 533
  • Copyright: © Ong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cholangiocarcinoma is a common malignancy with increasing incidence worldwide. Most patients are diagnosed at the advanced stage with poor survival rate. Laminin subunit γ2 (LAMC2) is a heparin binding‑associated gene involved in tumorigenesis and has been implicated in the prognosis of various types of cancers. However, it is unclear whether expression of LAMC2 is associated with the clinical outcome of patients with cholangiocarcinoma. In the present study, the role and prognostic value of LAMC2 expression in patients with cholangiocarcinoma was investigated. Clinical information and pathological characteristics were analyzed and the association between LAMC2 expression and clinical characteristics, pathological findings and patient outcomes, including metastasis‑free and disease‑specific survival, were investigated. Data from 182 patients with cholangiocarcinoma were evaluated. High LAMC2 expression was associated with higher tumor stage (P<0.001), large duct type (P=0.024) and poor histological grade (P=0.002). Kaplan‑Meier analysis showed high LAMC2 expression was associated with lower overall (P=0.003), disease‑specific (P=0.0025), local recurrence‑free (P<0.0001) and metastasis‑free survival (P<0.0001). Moreover, multivariate analysis demonstrated that increased LAMC2 expression was a significant predictive risk factor for overall [hazard ratio (HR) 1.713; P=0.034], disease‑specific (HR 2.011; P=0.039), local recurrence‑free (HR 2.721; P<0.001) and metastasis‑free survival (HR 3.117; P<0.001). Gene enrichment analysis using Gene Ontology showed that terms associated with LAMC2 upregulation were ‘regulation of platelet‑derived growth factor receptor‑βsignaling pathway’ and ‘platelet‑derived growth factor receptor‑β signaling pathway’. The present study indicated that LAMC2 was upregulated in cholangiocarcinoma tumor tissue and had an inverse association with overall, disease‑specific, local recurrence‑free and metastasis‑free survival in patients with cholangiocarcinoma. These results suggested that LAMC2 may serve as a potential biomarker for cholangiocarcinoma.
View Figures
View References

Related Articles

Journal Cover

December-2023
Volume 26 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ong KH, Hsieh Y, Lai H, Sun D, Chen T, Huang SK, Tian Y, Chou C, Shiue Y, Wu H, Wu H, et al: LAMC2 is a potential prognostic biomarker for cholangiocarcinoma. Oncol Lett 26: 533, 2023.
APA
Ong, K.H., Hsieh, Y., Lai, H., Sun, D., Chen, T., Huang, S.K. ... Kuo, Y. (2023). LAMC2 is a potential prognostic biomarker for cholangiocarcinoma. Oncology Letters, 26, 533. https://doi.org/10.3892/ol.2023.14120
MLA
Ong, K. H., Hsieh, Y., Lai, H., Sun, D., Chen, T., Huang, S. K., Tian, Y., Chou, C., Shiue, Y., Wu, H., Chan, T., Tsai, H., Li, C., Kuo, Y."LAMC2 is a potential prognostic biomarker for cholangiocarcinoma". Oncology Letters 26.6 (2023): 533.
Chicago
Ong, K. H., Hsieh, Y., Lai, H., Sun, D., Chen, T., Huang, S. K., Tian, Y., Chou, C., Shiue, Y., Wu, H., Chan, T., Tsai, H., Li, C., Kuo, Y."LAMC2 is a potential prognostic biomarker for cholangiocarcinoma". Oncology Letters 26, no. 6 (2023): 533. https://doi.org/10.3892/ol.2023.14120